

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

TEVA PHARMACEUTICALS)
INTERNATIONAL GMBH and)
TEVA PHARMACEUTICALS USA, INC.,)
)
Plaintiffs,)
)
v.)
)
ELI LILLY AND COMPANY,)
)
Defendant.)
)

Case No. 1:18-cv-12029-ADB

**DEFENDANT ELI LILLY AND COMPANY’S MOTION IN *LIMINE* NO. 8 TO
PRECLUDE THE TESTIMONY OF BRYAN MAUK**

Pursuant to Fed. R. Civ. P. 37(c)(1) and Local Rule 7.1, Defendant Eli Lilly and Company (“Lilly”) respectfully moves in *limine* to preclude Plaintiffs Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. (“Teva”) from calling Bryan Mauk as a witness at trial. The grounds for the motion are fully set forth in Lilly’s memorandum in support of this motion, and the declaration of Marta Garcia Daneshvar in support of Lilly’s motion with accompanying exhibits, filed concurrently with this motion.

REQUEST FOR ORAL ARGUMENT

Pursuant to Local Rule 7.1(d), Lilly requests oral argument on this motion.

Dated: September 16, 2022

/s/Andrea L. Martin

Andrea L. Martin (BBO 666117)
BURNS & LEVINSON LLP
125 High Street
Boston, MA 02110-1624
(617) 345-3000
amartin@burnslev.com

William B. Raich
Danielle A. Duszczyszyn
Denise Main
Pier D. DeRoo
Matthew Luneack
Yoonjin Lee
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, LLP
901 New York Avenue, NW
Washington, DC 20001-4413
William.Raich@finnegan.com
Danielle.Duszczyszyn@finnegan.com
Denise.Main@finnegan.com
Pier.DeRoo@finnegan.com
Matthew.Luneack@finnegan.com
Yoonjin.Lee@finnegan.com

Charles E. Lipsey
Ryan O'Quinn
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, LLP
1875 Explorer Street
Suite 800
Reston, VA 20190-6023
Charles.Lipsey@finnegan.com
Oquinnr@finnegan.com

Emily R. Gabranski (BBO 694417)
Marta Garcia Daneshvar
Lulu Wang (BBO 704042)
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, LLP
2 Seaport Lane
Boston, MA 02210-2001
Emily.Gabranski@finnegan.com
Marta.Garcia@finnegan.com
Lulu.Wang@finnegan.com

*Attorneys for Defendant
Eli Lilly and Company*

LOCAL RULE 7.1 CERTIFICATION

I hereby certify that, pursuant to Local Rule 7.1, counsel for Lilly conferred with counsel for Teva and attempted in good faith to resolve or narrow the issues presented in this motion. The parties conferred via telephone at least on September 9, 2022 and September 13, 2022 and by email at least on September 2, 8, 9, 12, 13, and 14, 2022. Teva opposes this motion.

/s/ Andrea L. Martin
Andrea L. Martin

CERTIFICATE OF SERVICE

I, Andrea L. Martin, hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non-registered participants on September 16, 2022.

/s/ Andrea L. Martin
Andrea L. Martin